Continue to meet or exceed healthcare partners’ expectations by providing on-time test results approximately 92 percent of the time.
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).
In October, due to demand from existing healthcare partners, CTS began testing blood donors for anti...
As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...
Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...
In August CTS begins source plasma testing as a new line of business to one of the largest plasma fr...
In July, the six viral marker assay conversion at CTS Dallas, Phoenix and Tampa laboratories was ach...